<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Reduced activity of endothelial nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) may be involved in <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation on atherosclerotic plaques, a major cause of <z:hpo ids='HP_0011009'>acute</z:hpo> coronary syndrome </plain></SENT>
<SENT sid="1" pm="."><plain>However, mechanisms of such increase in arterial thrombogenecity have not been fully understood </plain></SENT>
<SENT sid="2" pm="."><plain>We previously reported that long-term inhibition of NO synthesis by administration of N(G)-<z:chebi fb="13" ids="29785">nitro</z:chebi>-<z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> <z:chebi fb="36" ids="29309">methyl</z:chebi> <z:chebi fb="21" ids="35701">ester</z:chebi> (L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>) causes <z:hpo ids='HP_0000822'>hypertension</z:hpo> and activates vascular tissue angiotensin-converting enzyme (ACE) activity </plain></SENT>
<SENT sid="3" pm="."><plain>We used this model to investigate the mechanism by which long-term impairment of NO activity increases arterial thrombogenecity </plain></SENT>
<SENT sid="4" pm="."><plain>We observed cyclic flow variations (CFVs), a reliable marker of platelet <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e>, after the production of stenosis of the carotid artery in rats treated with L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> for 4 wk </plain></SENT>
<SENT sid="5" pm="."><plain>The thrombin <z:chebi fb="68" ids="48706">antagonist</z:chebi> argatroban suppressed the CFVs </plain></SENT>
<SENT sid="6" pm="."><plain>The CFVs were detected in rats receiving L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> plus hydralazine but not in rats receiving L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> plus an <z:chebi fb="2" ids="35457">ACE inhibitor</z:chebi> (imidapril) </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment with the <z:chebi fb="2" ids="35457">ACE inhibitor</z:chebi> imidapril, but not with hydralazine, prevented L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>-induced increases in carotid arterial ACE activity and attenuated tissue factor expression </plain></SENT>
<SENT sid="8" pm="."><plain>These results suggest that long-term inhibition of endothelial NO synthesis may increase arterial thrombogenecity at least in part through <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi>-induced induction of tissue factor and the resultant thrombin generation </plain></SENT>
<SENT sid="9" pm="."><plain>These data provide a new insight as to how endothelial NO exhibits antithrombogenic properties of the endothelium </plain></SENT>
</text></document>